Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Tremelimumab
Trade Name
Synonyms CP-675,206|Ticilimumab|CP-675206
Drug Descriptions

Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937).

DrugClasses CTLA4 Antibody 17 Immune Checkpoint Inhibitor 94

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Azacitidine + Durvalumab + Tremelimumab Azacitidine Durvalumab Tremelimumab 0 1
Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Bevacizumab Durvalumab Fluorouracil Leucovorin Oxaliplatin Tremelimumab 0 1
Bevacizumab + Durvalumab + Tremelimumab Bevacizumab Durvalumab Tremelimumab 0 0
BI 1361849 + Durvalumab + Tremelimumab BI 1361849 Durvalumab Tremelimumab 0 1
Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin Cisplatin Durvalumab Etoposide Tremelimumab 0 2
Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin Durvalumab Etoposide Tremelimumab 0 2
Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Carboplatin Durvalumab Gemcitabine Tremelimumab 0 2
Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin Durvalumab Nab-paclitaxel Tremelimumab 0 1
Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin Durvalumab Paclitaxel Tremelimumab 0 1
Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Cisplatin Durvalumab Fluorouracil Tremelimumab 0 1
Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin Durvalumab Gemcitabine Tremelimumab 0 1
CP-870,893 + Tremelimumab CP-870,893 Tremelimumab 1 0
Cyclophosphamide + Durvalumab + Tremelimumab Cyclophosphamide Durvalumab Tremelimumab 0 1
Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Durvalumab Fluorouracil Leucovorin Oxaliplatin Tremelimumab 0 1
Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab Gemcitabine Nab-paclitaxel Tremelimumab 0 1
Durvalumab + Guadecitabine + Tremelimumab Durvalumab Guadecitabine Tremelimumab 0 1
Durvalumab + Olaparib + Tremelimumab Durvalumab Olaparib Tremelimumab 0 1
Durvalumab + Personalized cancer vaccine + Tremelimumab Durvalumab Personalized cancer vaccine Tremelimumab 0 1
Durvalumab + Selumetinib + Tremelimumab Durvalumab Selumetinib Tremelimumab 0 1
Durvalumab + Tremelimumab Durvalumab Tremelimumab 2 68
GSK3359609 + Tremelimumab GSK3359609 Tremelimumab 0 1
LY3022855 + Tremelimumab LY3022855 Tremelimumab 0 1
mRNA-2752 + Tremelimumab Tremelimumab mRNA-2752 0 1
Olaparib + Tremelimumab Olaparib Tremelimumab 0 2
PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab PF-06755990 PF-06755992 Sunitinib Tremelimumab 0 1
Tavolimab + Tremelimumab Tavolimab Tremelimumab 0 2
Tremelimumab Tremelimumab 0 26


Additional content available in CKB BOOST